From ChildrensHealthDefense.org…
On Aug. 23, the U.S. Food and Drug Administration (FDA) issued its approval (also known as a license) for Pfizer’s Comirnaty COVID vaccine.
The FDA documents related to the vaccine’s approval are as difficult to understand as the new brand name is to pronounce.
According to the FDA, although Pfizer’s Comirnaty vaccine is now approved, considerable amounts of the vaccine will remain under Emergency Use Authorization (EUA).
Also, the approval of the Comirnaty vaccine was limited to adults over age 16 receiving their first two doses.
Vaccination with the EUA Pfizer-BioNTech or the Comirnaty vaccine in the 12- to 15-year age group, or providing a third booster dose of either, are still considered an unapproved use — however, those uses remain authorized under EUA.
